Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1B | Q9Y463 | 12/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.42 |
| ▸ | AURKA | O14965 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.42 |
| ▸ | FLT1 | P17948 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | CLK2 | P49760 | 3/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.42 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.42 |
| ▸ | PAK4 | O96013 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
| ▸ | LTK | P29376 | 2/20 | 0.42 |
| ▸ | GRK5 | P34947 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28912872 | 0.83 | DYRK1B (0.41) | DYRK1BDYRK1AAURKAJAK2MAP4K4 | |
| SCHEMBL29935923 | 0.79 | PADI4 (0.31) | — | |
| SCHEMBL23107943 | 0.79 | RET (0.31) | RETLRRK2 | |
| SCHEMBL28939697 | 0.76 | HCAR2 (0.38) | DYRK1BKDM4EALDH1A1MAPT | |
| SCHEMBL28554026 | 0.75 | DYRK1A (0.36) | DYRK1BDYRK1AAURKAJAK2MAP4K4 | |
| SCHEMBL28554025 | 0.75 | DYRK1A (0.36) | DYRK1BDYRK1AAURKAJAK2MAP4K4 | |
| SCHEMBL29009515 | 0.74 | IDO1 (0.39) | PIM1ALDH1A1LMNAMAPT | |
| SCHEMBL30508312 | 0.74 | DYRK1A (0.55) | DYRK1BDYRK1AAURKAJAK2MAP4K4 | |
| SCHEMBL1585071 | 0.74 | DYRK1A (0.55) | DYRK1BDYRK1AAURKAJAK2MAP4K4 | |
| SCHEMBL1592867 | 0.73 | DYRK1B (0.44) | DYRK1BDYRK1AAURKAJAK2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
| WO-2006130673-A1 | 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | PRKDC, PRKACA, ABL1 | DYRK1B 639/4885DYRK1A 612/4885AURKA 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.